Recently, the American pharmaceutical company Lilly registered a phase 3 new clinical trial TRIUMPH-3 study on the drug Retarutide for treating obese patients with cardiovascular disease. It is reported that Retarutide is the first GLP-1R/GCGR/GIPR agonist to enter the phase 3 clinical stage.

    The TRIUMPH-3 study is a randomized double-blind trial intended to include 1800 obese patients with a body mass index of ≥ 35kg/m2. The patient needs to be diagnosed with at least one cardiovascular disease and have experienced at least one failed diet loss. The main endpoint of this study is the change in body weight of subjects from baseline at week 80, while secondary endpoints include changes in waist circumference, total cholesterol, triglycerides, pharmacokinetics, and other indicators of subjects from baseline at week 80.

    Retarutide is a peptide drug developed by Lilly based on GIP peptide sequence that targets GLP-1R/GCGR/GIPR. The results of previous Phase 1a studies showed that compared to placebo, Retarutide reduced the weight of subjects by 8.96kg. At present, Lilly has completed the second phase clinical trial of Retatrutide for type 2 diabetes and obesity in 2022, and the specific results have not yet been announced.